Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 4
Submit an article Journal homepage
314
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia

Pieralessandro Lasalviaa Health Economics Department, Neuroeconomix, Bogota, ColombiaView further author information
,
Fabián Hernándeza Health Economics Department, Neuroeconomix, Bogota, ColombiaView further author information
,
Yaneth Gil-Rojasa Health Economics Department, Neuroeconomix, Bogota, ColombiaView further author information
&
Diego Rossellib Clinical Epidemiology and Biostatistics Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá, ColombiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0960-9480View further author information
ORCID Icon
Pages 821-827 | Received 31 Jul 2019, Accepted 03 Jun 2020, Published online: 07 Jul 2020

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now
Shahin Nargesi, Zeinab Dolatshahi, Aziz Rezapour, Vahid Alipour, Aghdas Souresrafil, Hiro Farabi, Seyed Arash Javadmoosavi, Mandana Safakhah & Najmeh Moradi. (2022) Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 543-554.
Read now

Articles from other publishers (2)

Andrés F. Cardona, Vaneza Ávila & Oscar Arrieta. (2023) Treatment for Advanced Non–Small Lung Cancer (NSCLC) with Mutated EGFR in Low- and Middle-Income Countries (LMICs) . Journal of Immunotherapy and Precision Oncology 6:4, pages 185-186.
Crossref
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera & Nikhil R. Thiruvengadam. (2022) Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood 140:25, pages 2697-2708.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.